Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Full Press Release Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 Travere Therapeutics to Report First Quarter 2025 Financial Results